These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21879811)

  • 1. A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.
    Chowdhury A; Chowdhury S; Tsai MY
    Leuk Lymphoma; 2012 Mar; 53(3):462-71. PubMed ID: 21879811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
    Grundy M; Seedhouse C; Russell NH; Pallis M
    BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrity of p53 associated pathways determines induction of apoptosis of tumor cells resistant to Aurora-A kinase inhibitors.
    Shionome Y; Yan L; Liu S; Saeki T; Ouchi T
    PLoS One; 2013; 8(1):e55457. PubMed ID: 23383195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
    Kretzner L; Scuto A; Dino PM; Kowolik CM; Wu J; Ventura P; Jove R; Forman SJ; Yen Y; Kirschbaum MH
    Cancer Res; 2011 Jun; 71(11):3912-20. PubMed ID: 21502403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein phosphatase 6 regulates mitotic spindle formation by controlling the T-loop phosphorylation state of Aurora A bound to its activator TPX2.
    Zeng K; Bastos RN; Barr FA; Gruneberg U
    J Cell Biol; 2010 Dec; 191(7):1315-32. PubMed ID: 21187329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
    Shimomura T; Hasako S; Nakatsuru Y; Mita T; Ichikawa K; Kodera T; Sakai T; Nambu T; Miyamoto M; Takahashi I; Miki S; Kawanishi N; Ohkubo M; Kotani H; Iwasawa Y
    Mol Cancer Ther; 2010 Jan; 9(1):157-66. PubMed ID: 20053775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
    Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
    Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152.
    Guo J; Anderson MG; Tapang P; Palma JP; Rodriguez LE; Niquette A; Li J; Bouska JJ; Wang G; Semizarov D; Albert DH; Donawho CK; Glaser KB; Shah OJ
    Pharmacogenomics J; 2009 Apr; 9(2):90-102. PubMed ID: 19188929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin.
    Momeny M; Zakidizaji M; Ghasemi R; Dehpour AR; Rahimi-Balaei M; Abdolazimi Y; Ghavamzadeh A; Alimoghaddam K; Ghaffari SH
    Med Oncol; 2010 Sep; 27(3):833-42. PubMed ID: 19763917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia.
    Donato NJ; Fang D; Sun H; Giannola D; Peterson LF; Talpaz M
    Biochem Pharmacol; 2010 Mar; 79(5):688-97. PubMed ID: 19874801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TPX2 overexpression in medullary thyroid carcinoma mediates TT cell proliferation.
    Yang X; Liu G; Xiao H; Yu F; Xiang X; Lu Y; Li W; Liu X; Li S; Shi Y
    Pathol Oncol Res; 2014 Jul; 20(3):641-8. PubMed ID: 24488334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells.
    Evans R; Naber C; Steffler T; Checkland T; Keats J; Maxwell C; Perry T; Chau H; Belch A; Pilarski L; Reiman T
    Leuk Lymphoma; 2008 Mar; 49(3):559-69. PubMed ID: 18297535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets.
    Krushkal J; Silvers T; Reinhold WC; Sonkin D; Vural S; Connelly J; Varma S; Meltzer PS; Kunkel M; Rapisarda A; Evans D; Pommier Y; Teicher BA
    Clin Epigenetics; 2020 Jun; 12(1):93. PubMed ID: 32586373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
    Payton M; Bush TL; Chung G; Ziegler B; Eden P; McElroy P; Ross S; Cee VJ; Deak HL; Hodous BL; Nguyen HN; Olivieri PR; Romero K; Schenkel LB; Bak A; Stanton M; Dussault I; Patel VF; Geuns-Meyer S; Radinsky R; Kendall RL
    Cancer Res; 2010 Dec; 70(23):9846-54. PubMed ID: 20935223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aurora kinases as targets in drug-resistant neuroblastoma cells.
    Michaelis M; Selt F; Rothweiler F; Löschmann N; Nüsse B; Dirks WG; Zehner R; Cinatl J
    PLoS One; 2014; 9(9):e108758. PubMed ID: 25268132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel mechanism for activation of the protein kinase Aurora A.
    Eyers PA; Erikson E; Chen LG; Maller JL
    Curr Biol; 2003 Apr; 13(8):691-7. PubMed ID: 12699628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
    Mahadevan D; Stejskal A; Cooke LS; Manziello A; Morales C; Persky DO; Fisher RI; Miller TP; Qi W
    Clin Cancer Res; 2012 Apr; 18(8):2210-9. PubMed ID: 22374334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.
    Mohan P; Castellsague J; Jiang J; Allen K; Chen H; Nemirovsky O; Spyra M; Hu K; Kluwe L; Pujana MA; Villanueva A; Mautner VF; Keats JJ; Dunn SE; Lazaro C; Maxwell CA
    Oncotarget; 2013 Jan; 4(1):80-93. PubMed ID: 23328114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
    Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
    Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of Xenopus Aurora A activation by TPX2.
    Eyers PA; Maller JL
    J Biol Chem; 2004 Mar; 279(10):9008-15. PubMed ID: 14701852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.